Complete remissions in 3 of 12 patients with pediatric acute lymphoblastic leukemia (ALL) during phase I testing of the anti-CD22 immunotoxin moxetumomab pasudotox

Category Primary study
JournalBlood
Year 2010
This article has no abstract
Epistemonikos ID: 607c555b85dd827f04e011872e1392513913f5f7
First added on: Feb 05, 2025